Last $51.85 USD
Change Today 0.00 / 0.00%
Volume 0.0
TEVJF On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
OTC US
Mexico
Frankfurt
As of 4:30 PM 06/16/13 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVJF) Snapshot

Open
--
Previous Close
$51.85
Day High
--
Day Low
--
52 Week High
04/1/14 - $52.26
52 Week Low
11/18/13 - $38.20
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
851.0M
EX-Date
08/21/14
P/E TM
--
Dividend
$483.85
Dividend Yield
2.58%
Current Stock Chart for TEVA PHARMACEUTICAL IND LTD (TEVJF)

teva pharmaceutical ind ltd (TEVJF) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical ind ltd (TEVJF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVJF) Key Developments

Ind-Swift In Stake Sale Talks With US Companies To Raise INR 2 Billion

Ind-Swift Laboratories Ltd. (BSE:532305) is in talks with two leading US based firms for strategic stake sale to mop up INR 2 billion, sources said. "Ind-Swift Lab is in talks with Teva Pharmaceutical Industries Limited (NYSE:TEVA) and Perrigo Company Public Limited Company (NYSE:PRGO) and the deal may involve selling up to a 30% stake or issue of fresh shares for a long-term order of 10 years for drug Temador-generic name for Temazolamide, used for treatment of cancer," said the sources. The funds will be used to expand existing manufacturing capacities. Ind-Swift has mandated E&Y to conduct due diligence to rope in strategic investors for the stake sale. N R Munjal, managing director, Ind-Swift Laboratories, however, told TOI, "We would not like to comment on our growth plans at this moment. We will inform the exchanges at an appropriate time as and when any such development arises."

Teva Pharmaceutical Industries Limited to Report Q2, 2014 Results on Jul 31, 2014

Teva Pharmaceutical Industries Limited announced that they will report Q2, 2014 results at 7:00 AM, US Eastern Standard Time on Jul 31, 2014

Teva Pharmaceutical Industries Limited Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist Inhaler

Teva Pharmaceuticals Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm (EIB) in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents (12 years of age and older) with asthma and exercise-induced bronchospasm (EIB). The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVJF:US $51.85 USD 0.00

TEVJF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.09 USD -0.77
AbbVie Inc $52.45 USD -1.30
Actavis plc $213.47 USD -2.08
Baxter International Inc $74.68 USD -1.41
Eli Lilly & Co $61.00 USD -1.62
View Industry Companies
 

Industry Analysis

TEVJF

Industry Average

Valuation TEVJF Industry Range
Price/Earnings 33.7x
Price/Sales 2.3x
Price/Book 2.0x
Price/Cash Flow 37.8x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.